Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Sponsor: Novartis Pharmaceuticals
Summary
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.
Official title: A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-06-03
Completion Date
2028-01-28
Last Updated
2026-05-27
Healthy Volunteers
No
Conditions
Interventions
QCZ484
QCZ484 once on Day 1
Inclisiran
Inclisiran once on Day 1
QCZ484 placebo
QCZ484 placebo once on Day 1
Inclisiran placebo
Inclisiran placebo once on Day 1